ATRC vs. TFX, ITGR, IART, ATEC, OFIX, SRDX, ANGO, ARAY, RMTI, and RSLS
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry.
AtriCure vs.
Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.
Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Teleflex has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.
In the previous week, Teleflex had 14 more articles in the media than AtriCure. MarketBeat recorded 25 mentions for Teleflex and 11 mentions for AtriCure. AtriCure's average media sentiment score of 1.10 beat Teleflex's score of 0.81 indicating that AtriCure is being referred to more favorably in the news media.
95.6% of Teleflex shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 1.4% of Teleflex shares are owned by company insiders. Comparatively, 3.2% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Teleflex currently has a consensus target price of $181.50, indicating a potential upside of 41.23%. AtriCure has a consensus target price of $49.44, indicating a potential upside of 52.79%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Teleflex.
Teleflex has a net margin of 7.85% compared to AtriCure's net margin of -9.61%. Teleflex's return on equity of 14.19% beat AtriCure's return on equity.
AtriCure received 48 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 69.66% of users gave AtriCure an outperform vote while only 58.57% of users gave Teleflex an outperform vote.
Summary
AtriCure beats Teleflex on 10 of the 18 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
This page (NASDAQ:ATRC) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy ATRC Stock Free ATRC Stock Alerts